Merit medical releases 12-month efficacy results for the single-arm arteriovenous graft (avg) cohort of the wrapsody® arteriovenous efficacy (wave) trial

In the avg cohort of the us pivotal trial, the merit wrapsody cell-impermeable endoprosthesis (cie) achieved 60.2% target lesion primary patency (tlpp) at 12 months. in the avg cohort of the us pivotal trial, the merit wrapsody cell-impermeable endoprosthesis (cie) achieved 60.2% target lesion primary patency (tlpp) at 12 months.
MMSI Ratings Summary
MMSI Quant Ranking